Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 11 · below the Ichimoku cloud · RSI 33 · MACD above its signal · at its 52-week low
| 0.5002 | 52-week high | +500050.02% |
| 0.001550 | Previous month high | +1450.00% |
| 0.000100 | Price now | |
| 0.000100 | R3 (classic) | −0.00% |
| 0.000100 | R2 (classic) | −0.00% |
| 0.000100 | R1 (classic) | −0.00% |
| 0.000100 | Pivot | −0.00% |
| 0.000100 | S1 (classic) | −0.00% |
| 0.000100 | S2 (classic) | −0.00% |
| 0.000100 | S3 (classic) | −0.00% |
| 0.000100 | Previous day high | −0.00% |
| 0.000100 | Previous day low | −0.00% |
| 0.000100 | Previous week high | −0.00% |
| 0.000100 | Previous week low | −0.00% |
| 0.000100 | Previous month low | −0.00% |
| 0.000100 | 52-week low | −0.00% |
None of the 29 investors followed here reported a position in GBLX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GBLX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for GBLX.
TimeframesDown on all 3 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | -40.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 33.3 | -75.0 | 0.0 | −80.0% | ||
| 2025 | 0.0 | -87.5 | -40.0 | -33.3 | 50.0 | 0.0 | -33.3 | 0.0 | 0.0 | 50.0 | 0.0 | 66.7 | −87.5% |
| 2024 | -18.7 | 15.4 | 11.7 | -3.1 | 92.6 | -34.8 | -1.8 | -10.0 | -23.6 | -96.4 | 2400.0 | -20.0 | −37.5% |
| 2023 | 8.3 | 7.6 | -12.2 | 0.3 | -34.6 | -11.0 | -4.5 | -0.3 | -2.0 | -26.5 | -13.9 | 3.2 | −63.6% |
| 2022 | 68.5 | -15.8 | -3.4 | -1.8 | -5.8 | -23.1 | 35.0 | 3.7 | -9.5 | 3.7 | -4.9 | -29.6 | −14.1% |
| 2021 | 43.0 | 25.2 | -17.4 | -4.9 | 8.4 | -12.0 | -19.5 | -16.1 | -6.1 | -4.8 | -18.5 | -26.0 | −51.1% |
| 2020 | -4.9 | -2.2 | -10.2 | -4.2 | 15.6 | -9.5 | -10.4 | 4.8 | -17.0 | 4.2 | 5.5 | 46.2 | +4.9% |
| 2019 | -3.7 | 21.0 | 0.9 | -13.3 | -14.2 | -9.2 | -1.0 | -15.5 | -8.4 | -23.2 | -23.1 | -30.0 | −74.8% |
| 2018 | -10.3 | -27.4 | -13.5 | 28.2 | -15.1 | -11.4 | -27.0 | 16.4 | -17.6 | -23.5 | -17.9 | -21.3 | −81.2% |
| 2017 | 15.5 | 1.7 | -7.7 | -28.1 | 7.6 | 0.4 | -8.9 | 0.0 | 3.7 | -11.5 | 4.2 | 246.5 | +154.5% |
| 2016 | 14.8 | 48.3 | -13.0 | -20.5 | 98.1 | 22.2 | -14.3 | -9.1 | 5.0 | 84.1 | -43.5 | 1.4 | +145.9% |
| 2015 | -12.5 | -14.3 | -22.6 | 19.6 | 56.1 | -10.3 | -4.3 | -17.9 | 32.9 | -15.2 | -20.2 | -45.5 | −62.5% |
| 2014 | -2.0 | -10.0 | 711.1 | -61.6 | 81.4 | -51.6 | 0.8 | -12.9 | -14.8 | 30.4 | -60.0 | -25.0 | −29.4% |
| 2013 | 33.3 | 75.0 | 0.0 | 0.0 | 0.0 | 0.0 | -7.1 | -61.5 | 28.0 | -6.2 | 66.7 | 2.0 | +70.0% |
| 2012 | -20.0 | 25.0 | -20.0 | 0.0 | 0.0 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -50.0 | −80.0% |
| 2011 | -13.4 | 0.0 | 27.3 | -42.9 | 15.4 | 104.8 | -47.1 | 0.0 | 50.0 | -33.3 | 0.0 | 50.0 | +18.1% |
| 2010 | 116.7 | -19.2 | -38.1 | -1.5 | -6.3 | 13.3 | -55.6 | -63.6 | 18.2 | 0.0 | -11.5 | 10.4 | −78.8% |
| 2009 | 1900.0 | 80.0 | -72.2 | 60.0 | -12.5 | 14.3 | 25.0 | 150.0 | 0.0 | 140.0 | 0.0 | 0.0 | +11900.0% |
| 2008 | 0.0 | -50.0 | 0.0 | 0.0 | 3900.0 | 50.0 | 26.7 | -31.6 | -26.9 | 0.0 | -47.4 | -50.0 | +400.0% |
| 2007 | -99.8 | 0.0 | -40.0 | 0.0 | 100.0 | 16.7 | -42.9 | 0.0 | 25.0 | -20.0 | -50.0 | 0.0 | −99.9% |
No analyst coverage for this instrument.
GB Sciences, Inc., a plant-based research and biopharmaceutical drug development company. The company offers cannabis inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, cytokine release syndrome, stress/anxiety/depression, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. is based in Las Vegas, Nevada.
No recent headlines.